Ovarian cancer is the gynecological malignant tumor with the highest mortality rate, known as the "silent killer". The global annual new incidence is about 314,000 cases, with 207,000 deaths.
Over 90% of ovarian cancer cases are epithelial ovarian cancer, including high-grade serous carcinoma (70%), endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, etc. About 15%–20% of cases are associated with BRCA1/BRCA2 gene mutations, and 20%–25% are related to hereditary tumor syndromes. Due to the lack of specific early symptoms and effective screening methods, over 70% of patients are diagnosed at an advanced stage (FIGO stage III–IV), with a high recurrence rate (up to 70% within 3 years after initial treatment) and a 5-year overall survival rate of only 30%–40% globally.
China has the second largest number of ovarian cancer debulking surgery cases in the world, with a complete gross resection (CGR) rate of over 80% for advanced ovarian cancer in top centers, on par with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center in the US. Top centers have rich experience in multi-organ resection for advanced cases, including bowel, liver, and diaphragm resection, significantly improving patient survival.
HIPEC combined with debulking surgery has been widely used in top Chinese centers, with an application rate of over 60% for advanced cases, which can significantly improve progression-free survival (PFS) and reduce recurrence risk. The application of robot-assisted minimally invasive surgery for early-stage and recurrent cases has grown rapidly, with a surgical volume ranking second in the world.
BRCA gene testing and HRD (homologous recombination deficiency) testing have been widely popularized in China, with a short cycle (7–14 days) and a cost of only 1/4–1/2 of that in Europe and America. PARP inhibitors have been approved and covered by national medical insurance in China, with an annual treatment cost of only 1/10–1/5 of that in the US, making maintenance therapy accessible to most patients.
The 5-year overall survival rate of advanced ovarian cancer in top Chinese centers exceeds 50%, which is significantly higher than the global average of 30%–40%. For platinum-sensitive recurrent ovarian cancer, the 5-year survival rate exceeds 35%, on par with top European and American centers.
The cost of primary debulking surgery + HIPEC for advanced ovarian cancer in top Chinese centers is only 12,000–18,000 USD, which is 1/5–1/3 of that in the US (80,000–120,000 USD). MDT consultation and surgery can be arranged within 1–2 weeks, while the waiting period in Europe and America is often 3–6 months.
Pelvic Floor Dysfunction is a series of chronic diseases caused by the damage or dysfunction of the pelvic floor muscles, ligaments, and fascia, with a global incidence of over 30% in adult women, and up to 40%–50% in postmenopausal women and multiparous women.
Core types include stress urinary incontinence (SUI), pelvic organ prolapse (POP, including uterine prolapse, cystocele, rectocele, and vaginal vault prolapse), female sexual dysfunction, and chronic pelvic pain. The main causes include pregnancy and vaginal delivery, aging, menopause, obesity, long-term increased abdominal pressure, and pelvic surgery history. The disease does not threaten life, but seriously affects women's quality of life, social activities, and mental health, and is known as the "social cancer".
China has the largest annual number of pelvic floor reconstructive surgery cases in the world (over 200,000 cases annually). The success rate of TVT-O surgery for stress urinary incontinence exceeds 95%, and the success rate of laparoscopic sacrocolpopexy for pelvic organ prolapse exceeds 90%, on par with top European and American centers. The recurrence rate of surgery is less than 10% within 5 years, lower than the global average.
The popularity rate of minimally invasive pelvic floor surgery in top Chinese centers exceeds 95%, with laparoscopic and robot-assisted surgery as the mainstream. The surgical trauma is small, the hospital stay is short (3–5 days), and the recovery is fast, which significantly reduces the risk of complications compared with traditional open surgery.
China's original "pelvic floor rehabilitation + integrated traditional Chinese and Western medicine" conservative treatment protocol has an effective rate of over 80% for mild to moderate PFD, avoiding surgery for most patients. Acupuncture and biofeedback combined therapy for stress urinary incontinence has an effective rate of over 85%, a unique advantage of Chinese treatment.
Top centers have rich experience in the treatment of recurrent PFD, complex pelvic organ prolapse, and combined urinary and bowel dysfunction, with MDT teams including gynecology, urology, anorectal surgery, and rehabilitation medicine to formulate personalized treatment plans, significantly improving the success rate of complex cases.
The cost of TVT-O surgery for stress urinary incontinence in top Chinese centers is only 3,000–5,000 USD, and the cost of laparoscopic sacrocolpopexy for pelvic organ prolapse is only 8,000–12,000 USD, which is 1/4–1/3 of that in the US. Surgery can be arranged within 1–2 weeks, while the waiting period in Europe and America is often 3–6 months.
